Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Madrigal Pharmaceuticals gains FDA approval for NASH medicine Rezdiffra

Madrigal Pharmaceuticals achieved FDA approval for Rezdiffra, focusing on market leadership and patient services.
Sales expected to be back-end loaded in 2024, with varying prescription dynamics and affordability considerations.
Company confident in revenue consensus but hasn't provided specific numbers, creating uncertainty for investors.
Emphasis on high unmet need, early positive feedback, and comprehensive patient support services.

Madrigal Pharmaceuticals excels in Q2 with Rezdiffra launch success

Madrigal Pharmaceuticals demonstrated strong financial performance and market acceptance of Rezdiffra in Q2 2024.
The company faces challenges in educating stakeholders and managing operational aspects of expansion.
Opportunities lie in global expansion, new market segments, and continued growth in sales and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.

Madrigal: Beyond NASH

-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled study in patients with non-alcoholic steatohepatitis (NASH) and fibrosis, that was initiated in March 2019 --   CONSHOHOCKEN, Pa., Dec.  18, 2019  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has dosed the first patient in its second Phase 3 clinical trial, MAESTRO-NAFLD-1 with its first-in-class, once daily, oral thyroid hormone receptor-beta selective agonist, resmetirom (MGL-3196). Madrigal initiated its first Phase 3 clinical program, MAESTRO-NASH, in NASH patients with advanced liver fibrosis (stages F2 and F3) in March 2019. The primary endpoint for that trial, after one year of treatment, is resolution of NASH; key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Additionally, clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of MAESTRO-NASH. [ clinicaltrials.gov/NCT03900429 ]

Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (

WEST CONSHOHOCKEN, Pa., Dec.  10, 2019  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today announced the pricing of the previously-announced underwritten secondary offering by investment funds affiliated with Bay City Capital LLC, of 1,200,000 shares of Madrigal’s common stock at the public offering price of $107.85 per share. In connection with the offering, the selling stockholders have granted the underwriter an option, exercisable for 30 days after December 10, 2019, to purchase up to 180,000 additional shares of common stock, at the public offering price, less underwriting discounts, from the selling stockholders. The offering is expected to close on or about December 13, 2019, subject to the satisfaction of customary closing conditions. Madrigal did not issue or offer any shares of common stock in the offering and will not receive any proceeds from the sale of shares in the offering.

Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

CONSHOHOCKEN, Pa., Dec.  10, 2019  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today announced the commencement of an underwritten secondary offering of 1,200,000 shares of Madrigal’s common stock by investment funds affiliated with Bay City Capital LLC. In connection with the offering, the selling stockholders intend to grant the underwriter an option, exercisable for 30 days after the date of entry into the underwriting agreement related to the offering, to purchase up to 180,000 additional shares of common stock, at the public offering price, less underwriting discounts, from the selling stockholders. Madrigal is not issuing or offering any shares of common stock in the offering and will not receive any proceeds from the sale of shares in the offering.

Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock

Allergan

CymaBay Therapeutics

Conatus Pharma

Galmed Pharmaceuticals

Intercept Pharma

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

NASH Scorecard Year to Date: The Winners and the Losers

Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH:

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

CONSHOHOCKEN, Pa., Nov.  06, 2019  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights:

Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

Assembly Biosciences

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

3 Things to Watch From the Pharmaceutical Industry's Liver Meeting

Which of these NASH-oriented biotechs is the better buy?

Better Buy:  Intercept Pharmaceuticals  vs.  Madrigal Pharmaceuticals

Madrigal is one of the more prominent NASH-targeted biopharma companies today.

Madrigal: A Basic Overview

Inogen

The following securities are falling knives, meaning their share prices have declined more than 59% over the last 52 weeks.

2 Falling Knives With No Debt

Biotech stocks Intercept Pharmaceuticals and Madrigal Pharmaceuticals were hit Thursday after the Food and Drug Administration cast doubt on a method of evaluating some liver disease drugs.

Biotech Stocks Tumble As FDA Doubts Method Of Testing Drugs

DexCom

Ionis Pharma

Intuitive Surgical

Masimo

Medical technology and biotech stocks were ravaged Wednesday on a "Medicare for All" proposal out of Washington and amid rising popularity for presidential candidate Bernie Sanders.

Medical Stocks Charred As They 'Feel The Bern' Of Single-Payer Proposal

Although possessing huge market opportunities, there is currently no ideal NASH candidate in the late clinical stage.

MGL-3196: Not Ideal, But Currently The Best

Liver Therapy Forum weekly digest provides an overview on what’s happening in the NASH landscape in 2019. This week focuses on Madrigal.

Madrigal And Resmetirom In NASH: Killing Liver Fat

News for Madrigal Pharmaceuticals Stock (MDGL)